Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy
Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy
复制标题
DOI：
10.1677/erc.1.01024
复制
发表时间：
2005-07-01
影响因子：
3.9
通讯作者：
Barrett-Lee, PJ
中科院分区：
文献类型：
--
作者：
Barrett-Lee, PJ
辅助化疗已被证明可以为乳腺癌患者提供生存获益，但尽管如此，一些患者仍然复发。因此，需要存在于原发肿瘤内的能够预测化疗敏感性或耐药性的分子标记。到目前为止，还没有任何单一标志物进入常规临床实践，但一些候选途径正在被广泛研究。本文总结了在此背景下生长因子信号传导和p53功能的现状。讨论了各种乳腺癌治疗环境中人表皮生长因子受体 2、拓扑异构酶 II 和 p53 表达的数据。
Adjuvant chemotherapy has been shown to provide survival benefits in patients with breast cancer, but some patients still relapse despite this. There is therefore a need for molecular markers present within the primary tumour that can predict for chemotherapy sensitivity or resistance. Until now, no single marker has emerged into routine clinical practice, but several candidate pathways are being extensively investigated. This paper summarises the current status of growth factor singalling and p53 function in this context. The data on human epidermal growth factor receptor-2, topoisomerase II and p53 expression in a variety of breast cancer treatment settings are discussed.